Commitments and Contingencies - Additional Information (Details) - Teva Agreement - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Loss Contingencies [Line Items]
Nonrefundable upfront payment	$ 6,000,000
Payment upon achievement of certain clinical and commercial milestones	135,000,000.0
Asset transfer and license agreement, termination period after written notice				120 days
Asset transfer and license agreement, termination period notice of breach				60 days
Asset transfer and license agreement termination notice period if bankruptcy petition filed				60 days
Milestone payments		$ 0	$ 0	$ 0	$ 0
Research and Development Expenses
Loss Contingencies [Line Items]
Milestone payments		$ 0	$ 0	$ 0	$ 0
Teva's GlycoPEGylated FGF21 Program
Loss Contingencies [Line Items]
Payment upon achievement of certain clinical and commercial milestones	67,500,000
Teva's Development Program
Loss Contingencies [Line Items]
Payment upon achievement of certain clinical and commercial milestones	$ 67,500,000